Agus DB - Search Results

1

Shazer RL, Luthringer D, Agus DB, Gross ME. Shazer RL, et al. Among authors: agus db. Clin Adv Hematol Oncol. 2004 Jun;2(6):393-5; discussion 396. Clin Adv Hematol Oncol. 2004. PMID: 16163211 No abstract available.

2

Update on HER-kinase-directed therapy in prostate cancer.

Gross ME, Jo S, Agus DB. Gross ME, et al. Among authors: agus db. Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.

3

Targeting the HER-kinase axis in cancer.

Gross ME, Shazer RL, Agus DB. Gross ME, et al. Among authors: agus db. Semin Oncol. 2004 Feb;31(1 Suppl 3):9-20. doi: 10.1053/j.seminoncol.2004.01.005. Semin Oncol. 2004. PMID: 15052539 Review.

4

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.

Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Shazer RL, et al. Among authors: agus db. BJU Int. 2006 Apr;97(4):691-7. doi: 10.1111/j.1464-410X.2006.05974.x. BJU Int. 2006. PMID: 16536755 Clinical Trial.

5

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.

Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Mink SR, et al. Among authors: agus db. Prostate. 2010 Aug;70(11):1201-10. doi: 10.1002/pros.21155. Prostate. 2010. PMID: 20564426

6

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.

Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross ME. Kani K, et al. Among authors: agus db. Prostate. 2013 Feb 15;73(3):306-15. doi: 10.1002/pros.22569. Epub 2012 Aug 21. Prostate. 2013. PMID: 22911164

7

Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.

Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Gross M, et al. Clin Cancer Res. 2007 Apr 1;13(7):1979-86. doi: 10.1158/1078-0432.CCR-06-1156. Clin Cancer Res. 2007. PMID: 17404077

8

Body image predicts quality of life in men with prostate cancer.

Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross ME, Agus DB. Taylor-Ford M, et al. Among authors: agus db. Psychooncology. 2013 Apr;22(4):756-61. doi: 10.1002/pon.3063. Epub 2012 Mar 15. Psychooncology. 2013. PMID: 22422671

9

Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping.

Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Christie KM, et al. Among authors: agus db. Psychooncology. 2009 May;18(5):508-14. doi: 10.1002/pon.1420. Psychooncology. 2009. PMID: 18756584

10

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors.

Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross ME, Meyerowitz BE. Eisenberg SA, et al. Among authors: agus db. Psychooncology. 2015 Feb;24(2):228-35. doi: 10.1002/pon.3590. Epub 2014 Jun 2. Psychooncology. 2015. PMID: 24891013

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters